论文部分内容阅读
随着大数据时代的到来,个人信息的经济价值逐渐被社会广泛关注。其中患者的个人信息,不仅医院应该着重加以保护,医药公司同样也负有不可推卸的责任。目前国内对这一问题的探讨多集中于医院,恰恰忽略了具备一定的关联性却商业性更强的医药公司对患者数据的利用和保护。立法上的欠缺、公民个人维权意识淡薄,都导致此类事件屡见不鲜。未来中国立法将参考国际通行做法进行变革,医药公司应提前做好准备,规避法律风险。
With the advent of the big data era, the economic value of personal information gradually gained widespread public concern. The patient’s personal information, not only the hospital should focus on protection, pharmaceutical companies also have unshirkable responsibility. At present, the discussion on this issue in our country is mostly focused on the hospital, just neglecting the utilization and protection of patient data by the pharmaceutical companies that have a certain degree of relevance but are more commercially viable. The lack of legislation and the weak awareness of individual citizens’ rights protection all lead to such incidents being commonplace. In the future, Chinese legislation will make reference to the prevailing international practices to make changes. Pharmaceutical companies should make preparations in advance to avoid legal risks.